{"url_path":"/sec/regn/8-k/2026-07-06/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-06","source_url":"https://www.sec.gov/Archives/edgar/data/872589/0001104659-26-080562-index.html","accession_number":"0001104659-26-080562","cik":"0000872589","ticker":"REGN","issuer_name":"REGENERON PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/872589/0001104659-26-080562-index.html","primary_entity_key":"0000872589","primary_entity_name":"REGENERON PHARMACEUTICALS, INC."},"word_count":311,"has_tables":true,"body_markdown":"false\n0000872589\n\n0000872589\n\n2026-07-06\n2026-07-06\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n \n\n**Pursuant to Section 13 or 15(d) of**\n\n**the\nSecurities Exchange Act of 1934**\n\n \n\n**Date of Report (Date of earliest event reported):\nJuly 6, 2026******\n\n \n\n**REGENERON PHARMACEUTICALS, INC.**\n\n**(Exact name of registrant as specified\nin its charter)**\n\n \n\n**New York**\n\n**(State or other\njurisdiction of incorporation)**\n\n \n\n**000-19034**\n \n**13-3444607**\n\n**(Commission**\n\n**File Number)**\n\n \n\n**(I.R.S.\nEmployer**\n\n**Identification\nNo.)**\n\n \n \n\n**777 Old Saw Mill River Road, Tarrytown, New York**\n \n**10591-6707**\n\n**(Address\nof principal executive offices)**\n \n**(Zip\nCode)**\n\n** **\n\n**Registrant’s telephone number,\nincluding area code: (914) 847-7000**\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions\nA.2. below):\n\n \n\n¨ Written\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n¨ Soliciting material\npursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n¨ Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n¨ Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle\nof each class\nTrading\nSymbol(s)\nName\nof each exchange on which registered\n\nCommon Stock – par value $0.001 per share\nREGN\nNASDAQ Global Select Market\n\n \n\nIndicate by check mark whether the\nregistrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or\nRule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).\n\n \n\nEmerging growth company ¨\n\n \n\nIf an emerging growth company, indicate by check mark if the\nregistrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards\nprovided pursuant to Section 13(a) of the Exchange Act. ¨"}